SCHEMBL5172

SCHEMBL5172

C[CH]CC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5241 0.87 — —
SCHEMBL5481 0.87 — —
SCHEMBL867085 0.84 CYP1A2 (0.40) —
SCHEMBL5276 0.84 — —
SCHEMBL4325 0.84 CYP1A2 (0.40) —
SCHEMBL866288 0.84 CYP1A2 (0.40) —
SCHEMBL5143 0.84 CYP1A2 (0.40) —
SCHEMBL7980525 0.80 ALDH1A1 (0.31) —
SCHEMBL10439855 0.80 — —
SCHEMBL311338 0.80 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 623 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423711-B Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof 建新公司 2024-03-15 — — CN claimed
US-11040981-B2 Pyrrolotriazine compounds and methods of inhibiting TAM kinases SYROS PHARMACEUTICALS, INC. (US) 2021-06-22 — — US claimed
US-20210147431-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES SYROS PHARMACEUTICALS INC (US) 2021-05-20 — — US claimed
CN-112368285-A Pyrrolotriazine compounds and methods of inhibiting TAM kinase 希洛斯医药品股份有限公司 2021-02-12 — — CN claimed
EP-3694860-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES Syros Pharmaceuticals, Inc. (US) 2020-08-19 — — EP claimed
WO-2019074962-A1 PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES SYROS PHARMACEUTICALS, INC. (US) 2019-04-18 — — WO claimed
US-10259802-B2 Bicyclic aza compounds as muscarinic M1 receptor antagonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-04-16 — — US claimed
US-20180258085-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS NXERA PHARMA UK LIMITED (GB) 2018-09-13 — — US claimed
US-9975890-B2 Bicyclic AZA compounds as muscarinic M1 receptor antagonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-05-22 — — US claimed
US-20180084782-A1 METHOD OF CONTROL OF STINKBUGS SYNGENTA PARTICIPATIONS AG (CH) 2018-03-29 — — US claimed
US-20160128996-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2016-05-12 — — US claimed
US-9266857-B2 Bicyclic AZA compounds as muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2016-02-23 — — US claimed
US-20150232443-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2015-08-20 — — US claimed
EP-2897948-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2015-07-29 — — EP claimed
WO-2014045031-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2014-03-27 — — WO claimed
WO-2010012793-A1 FUNGICIDE AMINOTHIAZOLE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2010-02-04 — — WO claimed
EP-1551403-B1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARM INC (US) 2009-04-29 — — EP claimed
CN-1720046-A 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia ARENA PHARM INC (US) 2006-01-11 — — CN claimed
EP-1551403-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA Arena Pharmaceuticals, Inc. (US) 2005-07-13 — — EP claimed
WO-2004032928-A1 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 — — WO claimed
Send feedback